873303--3/16/2010--AVI_BIOPHARMA

related topics

{product, candidate, development}

{stock, price, share}

{product, liability, claim}

{personnel, key, retain}

{stock, price, operating}

{control, financial, internal}

{property, intellectual, protect}

{provision, law, control}

{cost, regulation, environmental}

{regulation, government, change}

We will need additional funds to conduct our planned research and development efforts. If we fail to continue to attract significant capital, we may be unable to continue to successfully develop our products. Our products are in an early stage of research and development and may not be determined to be safe or effective. We rely on U.S. government contracts to support several important R D programs If we fail to receive or experience delays in receiving necessary regulatory approvals, we will be unable to develop and commercialize our product in a timely manner. If we lose key personnel or are unable to attract and retain additional, highly skilled personnel required for our activities, our business will suffer. Asserting, defending and maintaining our intellectual property rights could be challenging and costly, and our failure to do so could harm our ability to compete and impair the outcome of our operations. The pharmaceutical, biotechnology and academic environments are highly competitive and competing intellectual property could limit our ability to protect our products. We depend on our partners and contractors for critical functions. Therefore, if our collaborations or strategic relationships are unsuccessful, our business could be harmed. We may get unexpected positive or negative results or outcomes during any stage of product development. We have incurred net losses since our inception and we may not achieve or sustain profitability. Our ability to be successful against our competitors cannot be assured. We may be subject to clinical trial claims and our insurance may not be adequate to cover damages. We use hazardous substances in our research activities. Our right to issue preferred stock, and our classified Board of Directors and Oregon Anti-Takeover laws may delay a takeover attempt and prevent or frustrate any attempt to replace or remove the then current management and Board of Director s. Our stock price is volatile and may fluctuate due to factors beyond our control. The significant number of our shares of common stock eligible for future sale may cause the price of our common stock to fall. Our common stock is listed on The NASDAQ Global Market and we may not be able to maintain that listing, which may make it more difficult for investors to sell shares of our common stock. We do not expect to pay dividends in the foreseeable future.

Full 10-K form ▸

873303--3/16/2010--AVI_BIOPHARMA_INC